CAMBRIDGE, Mass., Feb. 4 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) announced today the appointment of Theresa
Heggie, formerly Vice President Global Marketing for the Anesthesia and
Critical Care business unit of Baxter Healthcare, to the new position of
General Manager, TKT Europe.
"Theresa has a proven commercial and European track record and we are
delighted to welcome her to our organization. Her experience will be valuable
to us as she assumes leadership of the TKT team that launched Replagal in
Europe, and then achieved consistent sales growth over the past three years.
They have marketed Replagal with an emphasis on the science and innovative
services for physicians and patients and established an important platform in
Europe for our new product launches. As we look to introduce additional
lysosomal storage disease products into the franchise, we intend to build on
this strong foundation," said Dr. David Pendergast, Chief Operating Officer of
TKT.
Ms. Heggie joins TKT Europe with over 20 years of healthcare experience
both in the United States and overseas. Early in her career she held sales
representative positions at Dow Chemical and Janssen Pharmaceutical before
assuming a variety of marketing positions of increasing responsibility at
Ohmeda Pharmaceutical Products Division (PPD) from 1991 to 1998. At Ohmeda,
Ms. Heggie directed the U.S. launch of Suprane, an inhaled anesthetic and the
pre-marketing plan for inhaled nitric oxide for the treatment of persistent
pulmonary hypertension in newborns. Following the 1998 acquisition of Ohmeda
PPD by Baxter, Ms. Heggie was named Vice President Anesthesia and Critical
Care, Europe, a business unit of Baxter's Medication Delivery Division, where
she had responsibility for marketing, sales, medical and regulatory affairs,
finance and logistics. At the end of her thirteen-year tenure at Baxter
(Ohmeda), Ms. Heggie held the position Vice President, Global Marketing of the
Anesthesia and Critical Care business unit and was responsible for the
establishment and management of their global marketing function, including
strategic planning and life cycle management for several key products. Ms.
Heggie, aged 44, received a B.Sc. from Cornell University.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily
focused on researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the company
markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's website at
http://www.tktx.com.
This press release contains forward-looking statements regarding TKT's
management structure, as well as statements containing the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends," "should," "could,"
"will," "may," and similar expressions. There are a number of important
factors that could cause the company's actual results to differ materially
from those indicated by such forward-looking statements, including, whether
TKT will be able to successfully manage its European operations; ability to
launch new products in Europe and other factors set forth under the caption
"Certain Factors Which May Affect Future Results" in the company's Quarterly
Report on Form 10-Q for the quarter ended September 30, 2004, which is on file
with the Securities and Exchange Commission and are incorporated herein by
reference. While the company may elect to update forward-looking statements
at some point in the future, the company specifically disclaims any obligation
to do so, even if its expectations change.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Sanofi-Avenits. Suprane(R) is a registered trademark of Baxter.
For More Information Contact:
Justine E. Koenigsberg
Senior Director, Corporate Communications
(617) 349-0271
Daniella M. Lutz
Corporate Communications Manager
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Justine E. Koenigsberg, Senior Director,
Corporate Communications, +1-617-349-0271; or Daniella M. Lutz,
Corporate Communications Manager, +1-617-349-0205 both of
Transkaryotic Therapies, Inc.
|
